Fig. 1: Overall survival (OS) curves in patients with head and neck neuroendocrine carcinoma.
From: Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma
OS in (a) all 27 patients and (b) in the 17 patients with locally advanced disease who received multimodal curative treatments. c Relapse-free survival (RFS) rate in the 17 patients with locally advanced disease who received multimodal curative treatments.
